4.8 Article

Humanized mouse model supports development, function, and tissue residency of human natural killer cells

Publisher

NATL ACAD SCIENCES
DOI: 10.1073/pnas.1705301114

Keywords

humanized mice; cancer immunotherapy; IL-15; NK cells; ILC

Funding

  1. Erwin Schrodinger Fellowship (Austrian Science Fund) [J3220-B19]
  2. NIH [1K99AI125065-01, T32 AI07019, T32 AR 7107-37, AI 089992]
  3. short-term grant abroad (KWA) scholarship (University of Vienna)
  4. Austrian Marshall Plan Foundation
  5. Leukemia and Lymphoma Society
  6. Netherlands Organization of Scientific Research
  7. Cancer Research Institute Irvington Fellowship Program
  8. Bill and Melinda Gates Foundation
  9. Howard Hughes Medical Institute

Ask authors/readers for more resources

Immunodeficient mice reconstituted with a human immune system represent a promising tool for translational research as they may allow modeling and therapy of human diseases in vivo. However, insufficient development and function of human natural killer (NK) cells and T cell subsets limit the applicability of humanized mice for studying cancer biology and therapy. Here, we describe a human interleukin 15 (IL15) and human signal regulatory protein alpha (SIRPA) knock-in mouse on a Rag2(-/-) Il2rg(-/-) background (SRG-15). Transplantation of human hematopoietic stem and progenitor cells into SRG-15 mice dramatically improved the development and functional maturation of circulating and tissue-resident human NK and CD8(+) T cells and promoted the development of tissue-resident innate lymphoid cell (ILC) subsets. Profiling of human NK cell subsets by mass cytometry revealed a highly similar expression pattern of killer inhibitory receptors and other candidate molecules in NK cell subpopulations between SRG15 mice and humans. In contrast to nonobese diabetic severe combined immunodeficient Il2rg(-/-) (NSG) mice, human NK cells in SRG-15 mice did not require preactivation but infiltrated a Burkitt's lymphoma xenograft and efficiently inhibited tumor growth following treatment with the therapeutic antibody rituximab. Our humanized mouse model may thus be useful for preclinical testing of novel human NK cell-targeted and combinatory cancer immunotherapies and for studying how they elicit human antitumor immune responses in vivo.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available